Melony A. Beatson

1.8k total citations · 1 hit paper
9 papers, 1.3k citations indexed

About

Melony A. Beatson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Melony A. Beatson has authored 9 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Melony A. Beatson's work include Prostate Cancer Treatment and Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Melony A. Beatson is often cited by papers focused on Prostate Cancer Treatment and Research (3 papers), Cancer Treatment and Pharmacology (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Melony A. Beatson collaborates with scholars based in United States. Melony A. Beatson's co-authors include Effie Nomicos, Hirsh D. Komarow, Patrick R. Murray, Sean Conlan, Maria L. Turner, Clay Deming, Heidi H. Kong, Julia A. Segre, Julia Oh and Elizabeth A. Grice and has published in prestigious journals such as Journal of Clinical Oncology, Genome Research and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Melony A. Beatson

8 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis

2012 1.3k citations Heidi H. Kong, Julia Oh et al. Genome Research profile →

Peers

Melony A. Beatson

DERMA

IA

MB

PHYSI

EPIDE

Hilary A. Jackson United States

Andrea Koreck Hungary

Itaru Dekio Japan

Anna Andersson Sweden

Kimberly S. Vasquez United States

Sheila M. F. Torres United States

Lucie Mondoulet France

Matthias Reiger Germany

Adam J. SanMiguel United States

Éric Guaguère France

Hilary A. Jackson United States

Melony A. Beatson

684 ×0.7

DERMA

630 ×1.2

IA

91 ×0.3

MB

174 ×0.9

PHYSI

134 ×0.8

EPIDE

Citations per year, relative to Melony A. Beatson Melony A. Beatson (= 1×) peers Hilary A. Jackson

Countries citing papers authored by Melony A. Beatson

Since Specialization

Citations

This map shows the geographic impact of Melony A. Beatson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melony A. Beatson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melony A. Beatson more than expected).

Fields of papers citing papers by Melony A. Beatson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melony A. Beatson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melony A. Beatson. The network helps show where Melony A. Beatson may publish in the future.

Co-authorship network of co-authors of Melony A. Beatson

This figure shows the co-authorship network connecting the top 25 collaborators of Melony A. Beatson. A scholar is included among the top collaborators of Melony A. Beatson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melony A. Beatson. Melony A. Beatson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Beg, Muhammad Shaalan, Nilofer S. Azad, Sandip Pravin Patel, et al.. (2016). A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy and Pharmacology. 78(3). 577–584. 9 indexed citations

2.

Beg, Muhammad Shaalan, Michael A. Morse, Sandip Pravin Patel, et al.. (2015). A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC).. Journal of Clinical Oncology. 33(3_suppl). 240–240. 2 indexed citations

3.

Duffy, Austin G., Muhammad Shaalan Beg, Tim F. Greten, et al.. (2015). A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F).. Journal of Clinical Oncology. 33(3_suppl). TPS499–TPS499. 2 indexed citations

4.

Beg, Muhammad Shaalan, Michael A. Morse, Benjamin Tan, et al.. (2015). A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC).. Journal of Clinical Oncology. 33(15_suppl). e14013–e14013. 1 indexed citations

5.

Figg, William D., Cindy H. Chau, Ravi A. Madan, et al.. (2013). Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. Clinical Genitourinary Cancer. 11(3). 229–237. 25 indexed citations

6.

Morse, Michael A., Sandip Pravin Patel, Melony A. Beatson, & Philip M. Arlen. (2013). A phase II study of NPC-1C: A novel therapeutic monoclonal antibody (mab) to treat pancreatic (P) and colorectal (CR) cancers.. Journal of Clinical Oncology. 31(15_suppl). 3070–3070.

7.

Kong, Heidi H., Julia Oh, Clay Deming, et al.. (2012). Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Research. 22(5). 850–859. 1262 indexed citations breakdown →

8.

Adesunloye, Bamidele, Xuan Huang, Yang‐Min Ning, et al.. (2012). Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(15_suppl). 4569–4569. 6 indexed citations

9.

Adesunloye, Bamidele, Xuan Huang, Yang‐Min Ning, et al.. (2012). Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 30(5_suppl). 207–207. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact